Technical Analysis for HOWL - Werewolf Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | -0.36% | |
| Stochastic Reached Oversold | Weakness | -0.36% | |
| Earnings Movers | Other | -0.36% | |
| Wide Bands | Range Expansion | -0.36% | |
| Down 3 Days in a Row | Weakness | -0.36% | |
| Down 4 Days in a Row | Weakness | -0.36% | |
| Oversold Stochastic | Weakness | -0.36% | |
| Fell Below 20 DMA | Bearish | -4.55% | |
| MACD Bearish Signal Line Cross | Bearish | -4.55% | |
| NR7 | Range Contraction | -4.55% |
| Alert | Time |
|---|---|
| Up 3% | about 2 hours ago |
| Up 2% | about 2 hours ago |
| Up 1% | about 3 hours ago |
| 60 Minute Opening Range Breakout | about 3 hours ago |
| Down 3% | about 4 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/08/2024
Werewolf Therapeutics, Inc. Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Health Sciences Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.1939 |
| 52 Week Low | 1.5735 |
| Average Volume | 184,494 |
| 200-Day Moving Average | 4.03 |
| 50-Day Moving Average | 6.12 |
| 20-Day Moving Average | 5.93 |
| 10-Day Moving Average | 6.12 |
| Average True Range | 0.48 |
| RSI (14) | 40.12 |
| ADX | 12.62 |
| +DI | 17.11 |
| -DI | 21.32 |
| Chandelier Exit (Long, 3 ATRs) | 5.46 |
| Chandelier Exit (Short, 3 ATRs) | 5.93 |
| Upper Bollinger Bands | 6.91 |
| Lower Bollinger Band | 4.95 |
| Percent B (%b) | 0.27 |
| BandWidth | 32.91 |
| MACD Line | -0.03 |
| MACD Signal Line | 0.03 |
| MACD Histogram | -0.0566 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.16 | ||||
| Resistance 3 (R3) | 6.20 | 6.02 | 6.04 | ||
| Resistance 2 (R2) | 6.02 | 5.85 | 6.00 | 6.00 | |
| Resistance 1 (R1) | 5.75 | 5.74 | 5.66 | 5.71 | 5.97 |
| Pivot Point | 5.57 | 5.57 | 5.53 | 5.55 | 5.57 |
| Support 1 (S1) | 5.30 | 5.40 | 5.21 | 5.26 | 4.99 |
| Support 2 (S2) | 5.12 | 5.29 | 5.10 | 4.96 | |
| Support 3 (S3) | 4.85 | 5.12 | 4.92 | ||
| Support 4 (S4) | 4.81 |
